Figure 4.
Kaplan-Meier curves for overall survival and tissue inhibitor of metalloproteinase 2 (TIMP-2) expression in 43 patients with ovarian cancer. No significant difference in overall survival time and TIMP-2 expression in cancer cells (A). Patients with enhanced immunoreactivity of TIMP-2 in the stromal compartment (B) and simultaneous overexpression in the tumor and stromal compartments (C) had an increased overall survival time. IRS, immunoreactive score.